Last updated: 12 July 2024 at 6:39pm EST

Dr. Keith Lamont Cummings M.B.A., M.D. Net Worth




The estimated Net Worth of Keith Lamont Cummings is at least $4.56 Million dollars as of 10 July 2024. Dr Cummings owns over 10,911 units of Pliant Therapeutics stock worth over $3,458,730 and over the last 4 years he sold PLRX stock worth over $1,099,054.

Dr D PLRX stock SEC Form 4 insiders trading

Dr has made over 15 trades of the Pliant Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 10,911 units of PLRX stock worth $126,131 on 10 July 2024.

The largest trade he's ever made was exercising 30,750 units of Pliant Therapeutics stock on 13 June 2023 worth over $63,960. On average, Dr trades about 10,643 units every 68 days since 2020. As of 10 July 2024 he still owns at least 282,115 units of Pliant Therapeutics stock.

You can see the complete history of Dr Cummings stock trades at the bottom of the page.





Dr. Keith Lamont Cummings M.B.A., M.D. biography

Dr. Keith Lamont Cummings M.B.A., M.D. is the Chief Financial Officer at Pliant Therapeutics.



How old is Dr D?

Dr D is 44, he's been the Chief Financial Officer of Pliant Therapeutics since . There are 4 older and no younger executives at Pliant Therapeutics. The oldest executive at Pliant Therapeutics, Inc. is Dr. Éric Lefebvre M.D., 57, who is the Chief Medical Officer.

What's Dr D's mailing address?

Keith's mailing address filed with the SEC is C/O PLIANT THERAPEUTICS, INC., 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at Pliant Therapeutics

Over the last 4 years, insiders at Pliant Therapeutics have traded over $16,925,448 worth of Pliant Therapeutics stock. The most active insiders traders include Group, Llc Green Jeremy Red..., Rock Ventures Iii, L.P.Thir... und Thomas A Mccourt. On average, Pliant Therapeutics executives and independent directors trade stock every 24 days with the average trade being worth of $221,612. The most recent stock trade was executed by Eric Lefebvre on 10 July 2024, trading 12,319 units of PLRX stock currently worth $142,408.



What does Pliant Therapeutics do?

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.



What does Pliant Therapeutics's logo look like?

Pliant Therapeutics, Inc. logo

Complete history of Dr Cummings stock trades at Pliant Therapeutics

Datum
#
Unternehmen
Insider
Trans.
Transaktion
Anzahl der Aktien Preis je Aktie Gesamtpreis Anzahl der Aktien nach Quelle
10 Jul 2024 Keith Lamont Cummings
Finanzvorstand
Verkauf 10,911 $11.56 $126,131
10 Jul 2024
282,115
2 May 2024 Keith Lamont Cummings
Finanzvorstand
Optionausübung 21,000 $2.08 $43,680
2 May 2024
271,713
17 Jan 2024 Keith Lamont Cummings
Finanzvorstand
Verkauf 9,781 $17.23 $168,527
17 Jan 2024
194,605
17 Jul 2023 Keith Lamont Cummings
Finanzvorstand
Verkauf 19,771 $18.01 $356,076
17 Jul 2023
203,999
13 Jun 2023 Keith Lamont Cummings
Finanzvorstand
Optionausübung 30,750 $2.08 $63,960
13 Jun 2023
185,020
9 Jun 2023 Keith Lamont Cummings
Finanzvorstand
Optionausübung 5,800 $2.08 $12,064
9 Jun 2023
154,270
30 Mar 2023 Keith Lamont Cummings
Finanzvorstand
Verkauf 9,960 $26.52 $264,139
30 Mar 2023
148,470
23 Jan 2023 Keith Lamont Cummings
Finanzvorstand
Optionausübung 30,000 $4.50 $135,000
23 Jan 2023
114,424
22 Dec 2022 Keith Lamont Cummings
Finanzvorstand
Optionausübung 4,000 $2.08 $8,320
22 Dec 2022
84,424
19 Dec 2022 Keith Lamont Cummings
Finanzvorstand
Verkauf 9,643 $19.10 $184,181
19 Dec 2022
80,424
3 Sep 2021 Keith Lamont Cummings
Finanzvorstand
Optionausübung 20,000 $2.08 $41,600
3 Sep 2021
67,621
5 Mar 2021 Keith Lamont Cummings
Finanzvorstand
Optionausübung 20,000 $2.08 $41,600
5 Mar 2021
47,621
21 Dec 2020 Keith Lamont Cummings
Finanzvorstand
Optionausübung 4,500 $2.08 $9,360
21 Dec 2020
27,621
1 Dec 2020 Keith Lamont Cummings
Finanzvorstand
Optionausübung 18,734 $3.66 $68,566
1 Dec 2020
41,855
5 Jun 2020 Keith Lamont Cummings
Finanzvorstand
Optionausübung 19,300 $2.08 $40,144
5 Jun 2020
19,300


Pliant Therapeutics executives and stock owners

Pliant Therapeutics executives and other stock owners filed with the SEC include: